CN113288997B - 一种具有减重降糖作用的组合物、制剂及其应用 - Google Patents
一种具有减重降糖作用的组合物、制剂及其应用 Download PDFInfo
- Publication number
- CN113288997B CN113288997B CN202110697156.XA CN202110697156A CN113288997B CN 113288997 B CN113288997 B CN 113288997B CN 202110697156 A CN202110697156 A CN 202110697156A CN 113288997 B CN113288997 B CN 113288997B
- Authority
- CN
- China
- Prior art keywords
- parts
- granules
- sieving
- composition
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 230000000694 effects Effects 0.000 title claims abstract description 35
- 239000008280 blood Substances 0.000 title claims abstract description 32
- 210000004369 blood Anatomy 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 46
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims abstract description 20
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 16
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 16
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 16
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 15
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 14
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 14
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 9
- 239000008187 granular material Substances 0.000 claims description 46
- 238000007873 sieving Methods 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 25
- 239000007779 soft material Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 14
- 239000000853 adhesive Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 11
- 239000004375 Dextrin Substances 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 8
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 8
- 235000019202 steviosides Nutrition 0.000 claims description 8
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 7
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 7
- 239000000845 maltitol Substances 0.000 claims description 7
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 7
- 235000010449 maltitol Nutrition 0.000 claims description 7
- 229940035436 maltitol Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229940013618 stevioside Drugs 0.000 claims description 7
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
- 240000005979 Hordeum vulgare Species 0.000 claims description 6
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 6
- 240000008042 Zea mays Species 0.000 claims description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 235000007215 black sesame Nutrition 0.000 claims description 6
- 235000005822 corn Nutrition 0.000 claims description 6
- 235000010413 sodium alginate Nutrition 0.000 claims description 6
- 239000000661 sodium alginate Substances 0.000 claims description 6
- 229940005550 sodium alginate Drugs 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 229940014259 gelatin Drugs 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- 229940095672 calcium sulfate Drugs 0.000 claims description 4
- 235000011132 calcium sulphate Nutrition 0.000 claims description 4
- 229960000913 crospovidone Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 4
- 239000000832 lactitol Substances 0.000 claims description 4
- 229960003451 lactitol Drugs 0.000 claims description 4
- 235000010448 lactitol Nutrition 0.000 claims description 4
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 abstract description 17
- 235000018291 probiotics Nutrition 0.000 abstract description 17
- 235000000346 sugar Nutrition 0.000 abstract description 17
- 235000019197 fats Nutrition 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 229920002472 Starch Polymers 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract description 2
- 239000005556 hormone Substances 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 abstract description 2
- 230000033001 locomotion Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 230000036186 satiety Effects 0.000 abstract description 2
- 235000019627 satiety Nutrition 0.000 abstract description 2
- 239000008107 starch Substances 0.000 abstract description 2
- 235000019698 starch Nutrition 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 3
- 239000000463 material Substances 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 15
- 230000000968 intestinal effect Effects 0.000 description 15
- 241000700159 Rattus Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000000529 probiotic effect Effects 0.000 description 10
- 239000008103 glucose Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 230000012010 growth Effects 0.000 description 6
- 235000013406 prebiotics Nutrition 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 241000186604 Lactobacillus reuteri Species 0.000 description 3
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 description 3
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 3
- 241000193749 Bacillus coagulans Species 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000193171 Clostridium butyricum Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 229940054340 bacillus coagulans Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- XWZAWHJNTHSHGD-SIDOVBMKSA-N (2S)-6-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]hexanamide Polymers CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccccc1)C(N)=O XWZAWHJNTHSHGD-SIDOVBMKSA-N 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明涉及一种具有减重降糖作用的组合物及其制备方法,通过在原料中添加植物乳杆菌、动物双歧杆菌、鼠李糖乳杆菌组成的复合益生菌,还添加适当重量比例的低聚甘露糖、吡咯喹啉醌、β‑烟酰胺单核苷酸、铁皮石斛提取物,在上述各原料协同作用下,本发明所述组合物能够促进肠道运动,调节肠道激素,有助于排出肠道垃圾,并且适度增加饱腹感,阻断减缓脂肪、淀粉、糖的吸收,达到减脂减重,降低血糖的作用。本发明所述组合物无副作用,可提高人体免疫力,适用人群更加广泛。
Description
技术领域
本发明属于生物医药技术领域,具体涉及一种具有减重降糖作用的组合物、制剂及其应用。
背景技术
目前,肥胖、2型糖尿病及心血管病发病率呈现爆炸式增长的趋势,并已成为世界性公共卫生问题。越来越多研究证实肥胖是2型糖尿病的发病及伴随并发症风险的核心环节,肥胖患病率的增加极大地加速了2型糖尿病的发病率。肥胖与激素分泌异常、胰岛素分泌缺陷等代谢紊乱有关,最终导致2型糖尿病,引发心血管疾病、肝脏、肾脏病变和癌症。肥胖不仅会增加糖尿病相关心血管并发症的发生率,同时也会增加微血管病的发生率。在长期肥胖的人群里,糖尿病,特别是2型糖尿病的患病率明显增加,可高达普通人群的4倍之多。
科学研究发现,肠道菌群与肥胖密切相关,肠道菌群也被视为人体器官一样重要的角色,通过改变肠道微生物组成来调节肠道菌群基因模式,达到肠道菌群转录组、蛋白质组和代谢组的改变,进而影响宿主的消化、吸收和代谢过程来影响宿主的体重。
日常饮食可以影响肠道菌群的组成。目前我国调节肠道菌群类的食品从原料组成可分以益生菌为主要原料的活菌类食品和以益生元为主要原料的非活菌类食品。益生菌是指能够促进肠内菌群生态平衡,对宿主起也能够的活的微生物制剂。常见的益生菌主要包括两大类,分别为双歧杆菌(Bifidobacterium)和乳杆菌(Lactobacillus)。摄取适量的益生菌,能对宿主产生一种或多种特殊的功能性健康益处,因此,益生菌在功能食品及药品中有个广阔的应用前景。益生元是指不易被消化的食品成分,通过选择性的刺激一种或几种细菌的生长与活性,而对寄主产生有益的影响,从而改善寄主健康的物质。
利用益生菌和益生元调节肠道菌群已成为一个研究热点。中国专利CN10151796A公开了一种形成易瘦体质的益生菌和益生元组合物,乳双歧杆菌0.5-6份、长双歧杆菌0.2-5份、罗伊氏乳杆菌0.5-8份、鼠李糖乳杆菌0.3-5份、嗜酸乳杆菌0.6-8份、嗜热链球菌0.1-3份、凝结芽孢杆菌0.5-3份、酪酸梭菌0.4-6份、动物双歧杆菌0.1-3份、两岐双歧杆菌0.1-3份、副干酪乳杆菌0.1-2份、植物乳杆菌0.1-3份、干酪乳杆菌0.1-2份和瑞士乳杆菌0.1-2份、水苏糖0.5-2份、菊粉0.5-3份、抗性糊精0.2-1份、低聚果糖0.5-2份、低聚木糖0.5-2份和低聚半乳糖0.5-2份。但上述组合物对于肠道菌群的调节不明显,减重和降糖效果并不理想。
发明内容
为了解决现有技术存在的以上问题,本发明提供了一种具有减重降糖作用的组合物、制剂及其应用。所述组合物具有不影响人体食欲,有效减轻体重,同时还能降低高血糖、预防高血脂等疾病,提高人体免疫力的功效。
本发明所采用的技术方案为:
一种具有减重降糖作用的组合物,原料组分包括:植物乳杆菌5-50份、动物双歧杆菌5-20份、鼠李糖乳杆菌5-20份、玉米低聚肽5-50份、甜菊糖苷0-20份、低聚甘露糖0-30份、低聚木糖0-20份、大麦壳粉0.5-3份、吡咯喹啉醌0.1—0.3份、β-烟酰胺单核苷酸0.05—0.2份、铁皮石斛提取物1-10份、黑芝麻粉0.5-20份。
进一步优选所述具有减重降糖作用的组合物的原料组分包括:植物乳杆菌10-50份、动物双歧杆菌8-20份、鼠李糖乳杆菌10-20份、玉米低聚肽20-50份、甜菊糖苷5-20份、低聚甘露糖10-30份、低聚木糖10-20份、大麦壳粉1-3份、吡咯喹啉醌0.2-0.3份、β-烟酰胺单核苷酸0.05-0.2份、铁皮石斛提取物1-10份、黑芝麻粉0.5-20份。
所述植物乳杆菌为植物乳杆菌PLH1405冻干粉,所述动物双歧杆菌为动物双歧杆菌乳亚种CP-9,所述鼠李糖乳杆菌为鼠李糖乳杆菌bv-77。
一种包括所述组合物的制剂。
所述制剂的剂型为片剂、胶囊剂、颗粒剂中的任意一种。
所述颗粒剂的制备方法,包括如下步骤:
(1)取各原料组分,经分别粉碎后,过筛,备用;
(2)将所述各原料进行混合,再依次加入填充剂、崩解剂和粘合剂,充分混合均匀,得到软材;
(3)将所述软材过筛,制得湿颗粒;
(4)将所述湿颗粒进行干燥,制得所述颗粒剂。
步骤(1)中,所述过筛为过100目筛;
所述填充剂为抗性糊精、乳糖醇、微晶纤维素、硫酸钙中的一种或多种;
所述崩解剂为聚山梨酯80、交联聚维酮、海藻酸钠中的一种或多种;
所述粘合剂为明胶、蔗糖、聚乙二醇、麦芽糖醇中的一种或多种;
步骤(3)中,所述过筛为过16目筛。
所述片剂的制备方法,包括如下步骤:
(1)取各原料组分,经分别粉碎后,过筛,备用;
(2)将所述各原料进行混合,再依次加入填充剂、崩解剂和粘合剂,充分混合均匀,得到软材;
(3)将所述软材过筛,制得湿颗粒;
(4)将所述湿颗粒进行干燥,制得颗粒;
(5)向所述颗粒中加入润滑剂,压片,制得片剂。
所述润滑剂为聚乙二醇、氢化植物油、滑石粉中一种或多种。
所述组合物在制备具有减重降糖作用的食品、保健品或药品中的应用。
本发明具体如下有益效果:
本发明所述的具有减重降糖作用的组合物,通过在原料中添加植物乳杆菌、动物双歧杆菌、鼠李糖乳杆菌组成的复合益生菌,还添加适当重量比例的低聚甘露糖、吡咯喹啉醌、β-烟酰胺单核苷酸、铁皮石斛提取物。其中,吡咯喹啉醌会缩短益生菌的迟缓期,发挥和生长因子一样作用,加快菌体生长速度,并提高菌体细胞量;β-烟酰胺单核苷酸能修复人体和益生菌的DNA损伤,延缓衰亡;低聚甘露糖被肠道有益菌双歧杆菌利用,而不能为肠道有害细菌产气荚梭菌所利用,肠道腐败细菌受到抑制、腐败产物显著减少,促进益生菌发酵食物中的碳水化合物,生成短链脂肪酸,降低血液和肝脏中的胆固醇和甘油三酸脂,促使血脂正常化,合成B族维生素;低聚甘露糖和甜菊糖苷热值低,不会引起血糖升高;在上述各原料协同作用下,本发明所述组合物能够促进肠道运动,调节肠道激素,有助于排出肠道垃圾,并且适度增加饱腹感,阻断减缓脂肪、淀粉、糖的吸收,达到减脂减重,降低血糖的作用。本发明所述组合物无副作用,可提高人体免疫力,适用人群更加广泛。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将对本发明的技术方案进行详细的描述。显然,所描述的实施病例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式,都属于本发明所保护的范围。
以下实施例中以1份代表1kg。需要说明的是,以下实施例中的各原料均为市售产品。
实施例1
本实施例提供一种具有减重降糖作用的片剂,原料组成如表1所示:
表1
本实施例所述具有减重降糖作用的片剂的制备方法:
(1)取主成分的各原料,经分别粉碎,过100目筛;
(2)将步骤(1)主成分的各原料进行混合15min,再加入5%的辅料,其中辅料成分为:聚山梨酯80溶液、抗性糊精、微晶纤维素、明胶(各辅料添加量如上表所示),充分混合均匀,制得软材;
(3)将所述软材过16目筛,制湿颗粒;
(4)将所述湿颗粒在32℃进行减压干燥3h,取出,整粒;
(5)向上述颗粒中加入适量滑石粉压片,滑石粉添加量为主辅料总质量的1/20,即得所述片剂。
实施例2
本实施例提供一种具有减重降糖作用的片剂,原料组成如表2所示:
表2
本实施例所述具有减重降糖作用的片剂的制备方法:
(1)取主成分的各原料,经分别粉碎,过100目筛;
(2)将步骤(1)主成分的各原料进行混合15min,再加入15%的辅料充分混合,其中辅料成分为:乳糖醇、硫酸钙、交联聚维酮、麦芽糖醇、明胶(各辅料添加量如上表所示),之后加入适量乙醇溶液,充分混合均匀,制得软材;
(3)将所述软材过16目筛,制湿颗粒;
(4)将所述湿颗粒在32℃进行减压干燥3h,取出,整粒;
(5)向上述颗粒中加入适量滑石粉和聚乙二醇进行压片,滑石粉添加量为主辅料总质量的1/20,聚乙二醇添加量为主辅料总质量的3%,即得所述片剂。
实施例3
本实施例提供一种具有减重降糖作用的片剂,原料组成如表3所示:
表3
本实施例所述具有减重降糖作用的片剂的制备方法:
(1)取主成分的各原料,经分别粉碎,过100目筛;
(2)将步骤(1)主成分的各原料进行混合15min,再加入15%的辅料,其中辅料成分为:微晶纤维素、抗性糊精、海藻酸钠、交联聚维酮、聚乙二醇、麦芽糖醇(各辅料之间配比如上表所示),充分混合均匀,制得软材;
(3)将所述软材过16目筛,制湿颗粒;
(4)将所述湿颗粒在32℃进行减压干燥3h,取出,整粒;
(5)向上述颗粒中加入适量滑石粉和氢化植物油进行压片,其中滑石粉添加量为主辅料总质量的1/20,氢化植物油添加量为主辅料总质量的2%,即得所述片剂。
实施例4
本实施例提供一种具有减重降糖作用的颗粒剂,原料组成如表4所示:
表4
原料 | 重量 | 类别 |
植物乳杆菌PLH1405 | 50份 | 主成分 |
动物双歧杆菌乳亚种CP-9 | 20份 | 主成分 |
鼠李糖乳杆菌bv-77 | 5份 | 主成分 |
玉米低聚肽 | 10份 | 主成分 |
甜菊糖苷 | 10份 | 主成分 |
低聚甘露糖 | 20份 | 主成分 |
低聚木糖 | 12份 | 主成分 |
大麦壳粉 | 1份 | 主成分 |
吡咯喹啉醌 | 0.3份 | 主成分 |
β-烟酰胺单核苷酸 | 0.2份 | 主成分 |
铁皮石斛提取物 | 8份 | 主成分 |
黑芝麻粉 | 9份 | 主成分 |
乳糖醇 | 40份 | 填充剂 |
抗性糊精 | 25份 | 填充剂 |
海藻酸钠 | 10份 | 崩解剂 |
交联聚维酮 | 3份 | 崩解剂 |
明胶 | 40份 | 粘合剂 |
麦芽糖醇 | 5份 | 粘合剂 |
本实施例所述具有减重降糖作用的颗粒剂的制备方法:
(1)取主成分的各原料,经分别粉碎,过100目筛;
(2)将步骤(1)主成分的各原料进行混合后,再按照表中用量加入各辅料进行混合15min,之后加入占主辅料总质量15%的乙醇溶液,充分混合均匀,制得软材;
(3)将所述软材过16目筛,制湿颗粒;
(4)将所述湿颗粒在32℃进行减压干燥3h,取出,整粒,分装,即得所述颗粒剂。
实施例5
本实施例提供一种具有减重降糖作用的颗粒剂,原料组成如表5所示:
表5
原料 | 重量 | 类别 |
植物乳杆菌PLH1405 | 10份 | 主成分 |
动物双歧杆菌乳亚种CP-9 | 8份 | 主成分 |
鼠李糖乳杆菌bv-77 | 20份 | 主成分 |
玉米低聚肽 | 5份 | 主成分 |
甜菊糖苷 | 16份 | 主成分 |
低聚甘露糖 | 30份 | 主成分 |
低聚木糖 | 20份 | 主成分 |
大麦壳粉 | 2.5份 | 主成分 |
吡咯喹啉醌 | 0.3份 | 主成分 |
β-烟酰胺单核苷酸 | 0.2份 | 主成分 |
铁皮石斛提取物 | 3份 | 主成分 |
黑芝麻粉 | 5份 | 主成分 |
硫酸钙 | 5份 | 填充剂 |
抗性糊精 | 50份 | 填充剂 |
海藻酸钠 | 10份 | 崩解剂 |
交联聚维酮 | 3份 | 崩解剂 |
聚乙二醇 | 7份 | 粘合剂 |
麦芽糖醇 | 30份 | 粘合剂 |
本实施例所述具有减重降糖作用的颗粒剂的制备方法:
(1)取主成分的各原料,经分别粉碎,过100目筛;
(2)将步骤(1)主成分的各原料进行混合后,再按照表中用量加入各辅料进行混合15min,之后加入占主辅料总质量15%的乙醇溶液,充分混合均匀,制得软材;
(3)将所述软材过16目筛,制湿颗粒;
(4)将所述湿颗粒在32℃进行减压干燥3h,取出,整粒,分装,即得所述颗粒剂。
实施例6
本实施例提供一种具有减重降糖作用的颗粒剂,原料组成如表6所示:
表6
原料 | 重量 | 类别 |
植物乳杆菌PLH1405 | 45份 | 主成分 |
动物双歧杆菌乳亚种CP-9 | 20份 | 主成分 |
鼠李糖乳杆菌bv-77 | 5份 | 主成分 |
玉米低聚肽 | 14份 | 主成分 |
甜菊糖苷 | 8份 | 主成分 |
低聚甘露糖 | 23份 | 主成分 |
低聚木糖 | 10份 | 主成分 |
大麦壳粉 | 1份 | 主成分 |
吡咯喹啉醌 | 0.1份 | 主成分 |
β-烟酰胺单核苷酸 | 0.2份 | 主成分 |
铁皮石斛提取物 | 10份 | 主成分 |
黑芝麻粉 | 9份 | 主成分 |
抗性糊精 | 70份 | 填充剂 |
海藻酸钠 | 15份 | 崩解剂 |
聚乙二醇 | 20份 | 粘合剂 |
麦芽糖醇 | 17份 | 粘合剂 |
本实施例所述具有减重降糖作用的颗粒剂的制备方法:
(1)取主成分的各原料,经分别粉碎,过100目筛;
(2)将步骤(1)主成分的各原料进行混合后,再按照表中用量加入各辅料进行混合15min,之后加入占主辅料总质量15%的乙醇溶液,充分混合均匀,制得软材;
(3)将所述软材过16目筛,制湿颗粒;
(4)将所述湿颗粒在32℃进行减压干燥3h,取出,整粒,分装,即得所述颗粒剂。
对比例1
本对比例提供一种具有减重降糖作用的片剂,与实施例1的区别仅在于不含植物乳杆菌PLH1405,不含鼠李糖乳杆菌bv-77。
对比例2
本对比例提供一种具有减重降糖作用的片剂,与实施例1的区别仅在于不含以下成分:甜菊糖苷、低聚木糖、吡咯喹啉醌、β-烟酰胺单核苷酸、铁皮石斛提取物。
对比例3
本对比例提供一种益生菌和益生元组合物,采用现有文献公开的方法制得,所述组合物的原料组成为:
益生菌组合物,按重量份数计包括:乳双歧杆菌4份、长双歧杆菌2份、罗伊氏乳杆菌3份、鼠李糖乳杆菌2份、嗜酸乳杆菌3份、嗜热链球菌1份、凝结芽孢杆菌1份、酪酸梭菌1份、动物双歧杆菌1.5份、两岐双歧杆菌1.5份、副干酪乳杆菌1份、植物乳杆菌1.5份、干酪乳杆菌1份和瑞士乳杆菌1份;
益生元混合物,按重量份数计包括:水苏糖、菊粉、抗性糊精、低聚果糖、低聚木糖和低聚半乳糖各0.5份。其中,水苏糖和抗性糊精的重量比为1:1。
辅料,按重量份数计包括:葡萄糖20份、食用香精10份、硬脂酸镁5份和二氧化硅5份。
将上述原料充分混合,制粒后,制得。
对比例4
本对比例提供一种益生菌组合物,采用现有文献公开的方法制得,所述组合物的原料组成为:植物乳杆菌50份,嗜酸乳杆菌20份,罗伊氏乳杆菌15份,青春双歧杆菌10份,动物双歧杆菌5份。每份益生菌组合物含有总数为50亿的活菌,辅料为麦芽糊精,重量为0.2g。
将上述原料充分混合,制粒后,制得。
实验例
不同方法制得组合物的功能性动物实验。
样品:实施例1-6和对比例1-4所述组合物。
高脂饲料配制重量比为:66.5%大小鼠维持饲料+10%猪油+20%蔗糖+2.5%胆固醇+1%胆酸钠。购自:上海集奇生物科技有限公司,产品代码:MS1606-10KG。
试验动物:选用体重为100-150g的SPF级Wistar大鼠,随机平均分为实验组(实施例1-6和对比例1-4,共10组)、高脂对照组和普通对照组,每组10只,雌雄各半。
试验方法:实验组和高脂对照组喂养高脂饲料,普通对照组喂养基础饲料,自由饮食、饮水,连续喂养30天。将受试物与1mL蒸馏水混合,实验组大鼠灌胃受试物(即:实施例1-6和对比例1-4所述组合物),用量为1.2g/kg·BW·日(人拟用剂量为4g/60kg·BW·日,相当于人拟用剂量的20倍),高脂对照组和普通对照组给予等量蒸馏水。每天观察动物的表现、行为、毒性表现和死亡情况。试验前对大鼠编号,并称量试验前后大鼠体重,喂养30后,禁食10小时,大鼠腹部主动脉采集血液、分离血清,利用酶法试剂盒检测大鼠的总胆固醇(TCH)、甘油三酯(TG)和血糖(GLU)的含量。
1.1受试物对大鼠体重的影响
各组动物生长发育、活动均正常,无中毒表现和死亡。试验前后体重变化如下表7所示。
表7-各组大鼠试验前后的体重
组别 | 试验前(g) | 试验后(g) | 平均增重(g) |
实施例1 | 125.3±10.2 | 134.6±10.4<sup>*</sup>° | 9.3 |
实施例2 | 118.6±9.3 | 124.8±11.1<sup>*</sup>° | 6.2 |
实施例3 | 127.3±11.4 | 135.8±12.7<sup>*</sup>° | 8.5 |
实施例4 | 131.5±10.5 | 137.1±15.1<sup>*</sup>° | 5.6 |
实施例5 | 121.1±13.6 | 128.3±14.2<sup>*</sup>° | 7.2 |
实施例6 | 116.8±12.7 | 123.5±14.6<sup>*</sup>° | 6.7 |
对比例1 | 125.6±12.3 | 142.5±12.6<sup>*</sup>° | 16.9 |
对比例2 | 123.2±13.4 | 142.9±15.6<sup>*</sup>° | 19.7 |
对比例3 | 115.8±14.2 | 133.4±13.4<sup>*</sup>° | 17.6 |
对比例4 | 128.7±14.5 | 142.5±10.4<sup>*</sup>° | 13.8 |
高脂对照组 | 125.9±12.5 | 174.8.5±14.5° | 48.9 |
普通对照组 | 124.2±13.8 | 170.5±12.6 | 46.3 |
注:°表示与普通对照组相比有显著性差异(P<0.05),*表示与高脂对照组相比有显著性差异(P<0.05)。
由上表7可知,在高脂饲养下,本发明提供的减重降糖组合物可以显著延缓大鼠体重增长,有效的控制体重增长。
1.2受试物对生化指标的影响
大鼠的总胆固醇、甘油三酯和血糖的含量如下表8所示。
表8-各组大鼠试验后的生化指标
注:°表示与普通对照组相比有显著性差异(P<0.05),*表示与高脂对照组相比有显著性差异(P<0.05)。
由上表8可知,本发明提供的益生菌组合物,能够有效降低大鼠总胆固醇、甘油三酯和血糖的含量,从而达到有效预防高血糖、高血脂等相关疾病的功效。
综上所述,本发明提供的减重降糖组合物安全可靠,具有显著的减重、降糖效果。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。
Claims (8)
1.一种具有减重降糖作用的组合物,其特征在于,原料组分包括:植物乳杆菌10-50份、动物双歧杆菌8-20份、鼠李糖乳杆菌10-20份、玉米低聚肽20-50份、甜菊糖苷5-20份、低聚甘露糖10-30份、低聚木糖10-20份、大麦壳粉1-3份、吡咯喹啉醌0.2-0.3份、β-烟酰胺单核苷酸0.05-0.2份、铁皮石斛提取物1-10份、黑芝麻粉0.5-20份,所述植物乳杆菌为植物乳杆菌PLH1405冻干粉,所述动物双歧杆菌为动物双歧杆菌乳亚种CP-9,所述鼠李糖乳杆菌为鼠李糖乳杆菌bv-77。
2.一种包括权利要求1所述的组合物的制剂。
3.根据权利要求2所述的制剂,其特征在于,所述制剂的剂型为片剂、胶囊剂或颗粒剂中的任意一种。
4.根据权利要求3所述的颗粒剂的制备方法,其特征在于,包括如下步骤:
(1)取各原料组分,经分别粉碎后,过筛,备用;
(2)将所述各原料进行混合,再依次加入填充剂、崩解剂和粘合剂,充分混合均匀,得到软材;
(3)将所述软材过筛,制得湿颗粒;
(4)将所述湿颗粒进行干燥,制得所述颗粒剂。
5.根据权利要求4所述的颗粒剂的制备方法,其特征在于,步骤(1)中,所述过筛为过100目筛;
所述填充剂为抗性糊精、乳糖醇、微晶纤维素、硫酸钙中的一种或多种;
所述崩解剂为聚山梨酯80、交联聚维酮、海藻酸钠中的一种或多种;
所述粘合剂为明胶、蔗糖、聚乙二醇、麦芽糖醇中的一种或多种;
步骤(3)中,所述过筛为过16目筛。
6.根据权利要求3所述的片剂的制备方法,其特征在于,包括如下步骤:
(1)取各原料组分,经分别粉碎后,过筛,备用;
(2)将所述各原料进行混合,再依次加入填充剂、崩解剂和粘合剂,充分混合均匀,得到软材;
(3)将所述软材过筛,制得湿颗粒;
(4)将所述湿颗粒进行干燥,制得颗粒;
(5)向所述颗粒中加入润滑剂,压片,制得片剂。
7.根据权利要求6所述的片剂的制备方法,其特征在于,所述润滑剂为聚乙二醇、氢化植物油、滑石粉中一种或多种。
8.权利要求1所述的组合物在制备具有减重降糖作用的食品、保健品或药品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110697156.XA CN113288997B (zh) | 2021-06-23 | 2021-06-23 | 一种具有减重降糖作用的组合物、制剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110697156.XA CN113288997B (zh) | 2021-06-23 | 2021-06-23 | 一种具有减重降糖作用的组合物、制剂及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113288997A CN113288997A (zh) | 2021-08-24 |
CN113288997B true CN113288997B (zh) | 2022-08-12 |
Family
ID=77329328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110697156.XA Active CN113288997B (zh) | 2021-06-23 | 2021-06-23 | 一种具有减重降糖作用的组合物、制剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113288997B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113662996A (zh) * | 2021-08-25 | 2021-11-19 | 广州市沐家健康产业有限公司 | 具有减肥作用的益生菌组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105985918A (zh) * | 2014-10-31 | 2016-10-05 | 安徽锦乔生物科技有限公司 | 抗肥胖的乳酸菌菌株及其在食品组成物以及医药组成物中的应用 |
CN106867930A (zh) * | 2016-12-29 | 2017-06-20 | 大连医科大学 | 植物乳杆菌plh1405及在制备治疗急性酒精中毒药物中的应用 |
CN110151796A (zh) * | 2019-05-09 | 2019-08-23 | 中科宜康(北京)生物科技有限公司 | 一种形成易瘦体质的益生菌和益生元组合物及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104522815B (zh) * | 2015-01-14 | 2016-07-06 | 三株福尔制药有限公司 | 一种益生菌发酵玛咖组合物及其制备方法和应用 |
-
2021
- 2021-06-23 CN CN202110697156.XA patent/CN113288997B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105985918A (zh) * | 2014-10-31 | 2016-10-05 | 安徽锦乔生物科技有限公司 | 抗肥胖的乳酸菌菌株及其在食品组成物以及医药组成物中的应用 |
CN106867930A (zh) * | 2016-12-29 | 2017-06-20 | 大连医科大学 | 植物乳杆菌plh1405及在制备治疗急性酒精中毒药物中的应用 |
CN110151796A (zh) * | 2019-05-09 | 2019-08-23 | 中科宜康(北京)生物科技有限公司 | 一种形成易瘦体质的益生菌和益生元组合物及其应用 |
Non-Patent Citations (2)
Title |
---|
"Study of Probiotic Effects of Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus plantarum 299v Strains on Biochemical and Morphometric Parameters of Rabbits after Obesity Induction";Assia Bouaziz et al.;《Biology》;20210207;第10卷;第1-24页 * |
"山西老陈醋源植物乳杆菌173对II型糖尿病大鼠的降血糖机制";许女 等;《中国食品学报》;20201231;第20卷(第12期);第131-140页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113288997A (zh) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110151796B (zh) | 一种形成易瘦体质的益生菌和益生元组合物及其应用 | |
CN108157973B (zh) | 一种有益糖脂代谢功能的益生菌组合物及其制剂和应用 | |
Patel et al. | The current trends and future perspectives of prebiotics research: a review | |
Honda et al. | Anti-diabetic effects of lactic acid bacteria in normal and type 2 diabetic mice | |
KR101992537B1 (ko) | 신규한 락토바실러스 사케이 및 이를 포함하는 조성물 | |
CN111956676A (zh) | 一种包含人参提取物和益生菌的微生态制剂及其制备方法和应用 | |
CN109125525B (zh) | 防治心血管疾病的组合物及其制备方法和应用 | |
CN109419816B (zh) | 解纤维素拟杆菌在预防和/或治疗心脏疾病方面的应用 | |
KR20190000450A (ko) | 유산균, 노루궁뎅이버섯 추출물 및 은행잎 추출물을 포함하는 인지기능 또는 기억능력 개선용 식품 조성물 | |
CN111557404A (zh) | 助消化益生菌固体饮料及其制备方法 | |
CN109315769A (zh) | 一种用于改善人体肠内环境的组合物及其制备方法 | |
KR20230005057A (ko) | 락토바실러스 속 균주 및 한약재를 포함하는 병용 요법을 이용한 항노화 조성물 | |
CN113288997B (zh) | 一种具有减重降糖作用的组合物、制剂及其应用 | |
CN111000246A (zh) | 一种辅助降甘油三酯的益生菌膳食纤维组合物及其应用、保健品 | |
KR101135290B1 (ko) | 유산균을 기본으로 효소, 트레할로스, 치자추출물을 혼합하여 정장기능 및 소화기능이 강화된 건강기능식품 조성물 | |
CN110024932A (zh) | 一种用于减肥、改善腹泻、调整菌群的黑木耳提取物固体饮料配方及其制备方法 | |
CN107259287B (zh) | 一种显著促进肠道益生菌生长的固体饮料及其制备方法 | |
CN116622587A (zh) | 合成生物学方法制备的益生菌及其组合物和应用 | |
KR102000170B1 (ko) | 체지방 감소 및 장관면역활성 증진을 위한 건강보조식품 | |
CN110869035B (zh) | 沙氏别样杆菌在制备预防和/或治疗脂质代谢性相关疾病组合物中的应用 | |
CN113559132A (zh) | 一种有益糖脂代谢的益生菌组合物及其制备方法 | |
KR102077720B1 (ko) | 비만 억제 활성을 갖는 페디오코커스 에시디락티시 ao22 균주 및 이를 포함하는 비만 개선 또는 치료용 조성물 | |
CN106974940B (zh) | 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用 | |
CN106974939B (zh) | 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用 | |
CN115404187B (zh) | 一种体重管理及减压的益生菌组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |